ArticleJapanese journal of clinical oncology2024
Squamous cell carcinoma of the eyelid.
Article in Japanese journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 20 citations in OpenAlex.
- Article
- Poly(3-hydroxybutyrate)-Based Biomimetic Materials Encapsulated with Amide Derivatives of Chlorin-e6 for Advanced Photodynamic Therapy.Nanomaterials (Basel, Switzerland) · 2026Article
- Severe exposure keratopathy secondary to oncologic surgery in a patient with epidermodysplasia verruciformis.Dermatology online journal · 2026Article
- Malignant Eyelid Tumors in Italy (2020-2024): Toward Personalized Epidemiologic Insights from Two Referral Centers.Journal of personalized medicine · 2025Article
- An Unresectable Eyelid Squamous Cell Carcinoma Treated With Concurrent Chemoradiation Therapy.Cureus · 2025Article
- Squamous cell carcinoma of the eyelid: A rare tumor with unusual metastasis: A case report.Radiology case reports · 2024Article
- Metachronous Human Papillomavirus (HPV)-Related Eye Carcinoma in Previously Metastatic Breast Cancer: A Case Report.Cureus · 2024Article
- Surgical management of periocular squamous cell carcinoma: case report.Journal of medicine and life · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eyelid squamous cell carcinoma is a major type of rare eyelid cancer, together with basal cell carcinoma and sebaceous gland carcinoma. It is a painless disease that progresses slowly and is often detected by the appearance of nodules or plaques. Risk factors include exposure to ultraviolet light, fair skin, radiation and human papillomavirus infection. The standard treatment is surgical removal, and in cases of orbital invasion, orbital content removal is required. If sentinel node biopsy reveals a high risk of lymph node metastasis, adjuvant radiotherapy may be considered. Local chemotherapy, such as imiquimod and 5-fluorouracil, may be used for eyelid squamous cell carcinoma in situ. When surgery or radiotherapy is not recommended for distant metastases or locally advanced disease, drug therapy is often according to head and neck squamous cell carcinoma in Japan. The treatment often requires a multidisciplinary team to ensure the preservation of function and cosmetic appearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.